학술논문
MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate.
Document Type
Academic Journal
Author
Casanova I; Department of Neurology, Torrejon University Hospital, 28850 Madrid, Spain.; School of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain.; Domínguez-Mozo MI; Research Group in Environmental Factors of Neurodegenerative Diseases, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.; De Torres L; Department of Neurology, Torrejon University Hospital, 28850 Madrid, Spain.; Aladro-Benito Y; Department of Neurology, Getafe University Hospital, 28905 Madrid, Spain.; García-Martínez Á; Research Group in Environmental Factors of Neurodegenerative Diseases, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.; Gómez P; Department of Neurology, Torrejon University Hospital, 28850 Madrid, Spain.; School of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain.; Abellán S; Department of Neurology, Torrejon University Hospital, 28850 Madrid, Spain.; De Antonio E; Department of Radiology, Torrejon University Hospital, 28850 Madrid, Spain.; Álvarez-Lafuente R; Research Group in Environmental Factors of Neurodegenerative Diseases, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Source
Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2227-9059
Abstract
MicroRNAs (miRNAs) are promising biomarkers in multiple sclerosis (MS). This study aims to investigate the association between a preselected list of miRNAs in serum with therapeutic response to Glatiramer Acetate (GA) and with the clinical evolution of a cohort of relapsing-remitting MS (RRMS) patients. We conducted a longitudinal study for 5 years, with cut-off points at 2 and 5 years, including 26 RRMS patients treated with GA for at least 6 months. A total of 6 miRNAs from a previous study (miR-9.5p, miR-126.3p, mir-138.5p, miR-146a.5p, miR-200c.3p, and miR-223.3p) were selected for this analysis. Clinical relapse, MRI activity, confirmed disability progression (CDP), alone or in combination (No Evidence of Disease Activity-3) (NEDA-3), and Expanded Disability Status Scale (EDSS), were studied. After multivariate regression analysis, miR-9.5p was associated with EDSS progression at 2 years (β = 0.23; 95% CI: 0.04-0.46; p = 0.047). Besides this, mean miR-138.5p values were lower in those patients with NEDA-3 at 2 years ( p = 0.033), and miR-146a.5p and miR-126.3p were higher in patients with CDP progression at 2 years ( p = 0.044 and p = 0.05 respectively. These results reinforce the use of microRNAs as potential biomarkers in multiple sclerosis. We will need more studies to corroborate these data and to better understand the role of microRNAs in the pathophysiology of this disease.